Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | -1.75% | -6.33% | -38.24% |
May. 14 | Conduit Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 19 | Conduit Pharmaceuticals Inc. Appoints Joanne Holland as Chief Scientific Officer | CI |
Valuation
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Capitalization 1 | - | 331.3 |
Enterprise Value (EV) 1 | - | 328.1 |
P/E ratio | - | -51 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | - | - |
FCF Yield | - | - |
Price to Book | - | -735 x |
Nbr of stocks (in thousands) | - | 72,814 |
Reference price 2 | 10.25 | 4.550 |
Announcement Date | 7/11/23 | 4/16/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -2.918 | -3.086 | -5.262 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -3.657 | -4.887 | -0.535 |
Net income 1 | -3.657 | -4.887 | -0.535 |
Net margin | - | - | - |
EPS | - | - | -0.0892 |
Free Cash Flow | - | - | - |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 7/11/23 | 7/11/23 | 4/16/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 0.75 | 2.01 | - |
Net Cash position 1 | - | - | 3.24 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | - | - |
ROE (net income / shareholders' equity) | - | 61% | 10.1% |
ROA (Net income/ Total Assets) | - | - | -91% |
Assets 1 | - | - | 0.588 |
Book Value Per Share | - | - | -0.0100 |
Cash Flow per Share | - | - | 0.0600 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 7/11/23 | 7/11/23 | 4/16/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-38.24% | 211M | |
+57.08% | 59.34B | |
+43.00% | 40.24B | |
-5.43% | 39.88B | |
-5.56% | 28.55B | |
+16.40% | 27.26B | |
-20.49% | 19.23B | |
+33.17% | 12.61B | |
+3.22% | 12.49B | |
+24.37% | 12.28B |
- Stock Market
- Equities
- CDT Stock
- Financials Conduit Pharmaceuticals Inc.